Insight onto the Pathophysiology and Clinical Complications of Thalassemia Intermedia

REFERENCES

• Weatherall DJ. Thalassaemia: the long road from bedside to genome. Nat Rev Genet. 2004;5: 625–631.
   PubMed Web of Science ®Google Scholar
• Sturgeon P, Itano HA, Bergren WR. Genetic and biochemical studies of intermediate types of Cooley's anaemia. Br J Haematol. 1955l;1:264–277.
   PubMed Web of Science ®Google Scholar
• Galanello R, Cao A. Relationship between genotype and phenotype. Thalassemia intermedia. Ann NY Acad Sci. 1998;850:325–333.
   PubMed Web of Science ®Google Scholar
• Weatherall D. The molecular basis for phenotypic variability of the common thalassaemias. Mol Med Today. 1995;1:15–20.
   PubMedGoogle Scholar
• Taher A, Ismaeel H, Cappellini MD. Thalassaemia Intermedia: revisited. Blood Cells Mol Dis. 2006;37:12–20.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Eleftheriou A, et al. Guidelines for the Clinical Management of Thalassaemia. 2nd revised edition. Nicosia, Cyprus: Thalassaemia International Federation; 2008.
   Google Scholar
• Camaschella C, Mazza U, Roetto A, et al. Genetic interactions in thalassemia intermedia: analysis of beta-mutations, alpha-genotype, gamma-promoters, and beta-LCR hypersensitive sites 2 and 4 in Italian patients. Am J Hematol. 1995;48:82–87.
   PubMed Web of Science ®Google Scholar
• Camaschella C, Kattamis AC, Petroni D, et al. Different hematological phenotypes caused by the interaction of triplicated alpha-globin genes and heterozygous beta-thalassemia. Am J Hematol. 1997;55:83–88.
   PubMed Web of Science ®Google Scholar
• Sampietro M, Cazzola M, Cappellini MD, et al. The triplicated alpha-gene locus and heterozygous beta thalassaemia: a case of thalassaemia intermedia. Br J Haematol. 1983;55:709–710.
   PubMed Web of Science ®Google Scholar
• Beris P, Solenthaler M, Deutsch S, et al. Severe inclusion body beta-thalassaemia with haemolysis in a patient double heterozygous for beta(0)-thalassaemia and quadruplicated apla-globin gene arrangement of the anti-4.2 type. Br J Haematol. 1999;105:1074–1080.
   PubMed Web of Science ®Google Scholar
• Taher A, Shammaa D, Bazarbachi A, et al. Absence of JAK2 V617F mutation in thalassemia intermedia patients. Mol Biol Rep. 2009;36:1555–1557.
   Google Scholar
• Weatherall DJ. Thalassemia intermedia: cellular and molecular aspects. J Hematol. 2001;86: 186–188.
   Google Scholar
• Ho PJ, Hall GW, Luo LY, et al. Beta-thalassaemia intermedia: is it possible consistently to predict phenotype from genotype? Br J Haematol. 1998;100:70–78.
   PubMed Web of Science ®Google Scholar
• Rund D, Oron-Karni P, Filon D, et al. Genetic analysis of beta-thalassemia intermedia in Israel: diversity of mechanisms and unpredictability of phenotype. Am J Hematol. 1997;54:16–22.
   PubMed Web of Science ®Google Scholar
• Phadke SR, Agarwal S. Phenotype score to grade the severity of thalassemia intermedia. Indian J Pediatr. 2003;70:477–481.
   Google Scholar
• Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica. 1995;80:58–68.
   PubMed Web of Science ®Google Scholar
• Olivieri NF. The beta-thalassemias. N Engl J Med. 1999;341:99–109.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cerino M, Marelli S, et al. Thalassemia intermedia: clinical aspects and management. Haematologica. 2001;86:194–196.
   Google Scholar
• Taher A, Abou-Mourad Y, Abchee A, et al. Pulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication? Hemoglobin. 2002;26:107–112.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97:3411–3416.
   PubMed Web of Science ®Google Scholar
• Taher AT, Otrock ZK, Uthman I, et al. Thalassemia and hypercoagulability. Blood Rev. 2008;22:283–292.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol. 2007;139:3–13.
   PubMed Web of Science ®Google Scholar
• Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in b-thalassemia. Haematologica. 2007;92:583–588.
   PubMed Web of Science ®Google Scholar
• Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13:1096–1101.
   PubMed Web of Science ®Google Scholar
• Valore EV, Ganz T. Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol Dis. 2008;40:132–138.
   PubMed Web of Science ®Google Scholar
• Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood. 2008;111:924–931.
   PubMed Web of Science ®Google Scholar
• Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest. 2007;117:1926–1932.
   PubMed Web of Science ®Google Scholar
• Pakbaz Z, Fischer R, Fung E, et al. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer. 2007;49:329–332.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rigon F, Merlo L, et al. Thalassemia minor, the Gilbert mutation, and the risk of gallstones. Haematologica. 2003;88:1106–1109.
   PubMed Web of Science ®Google Scholar
• Chehal A, Aoun E, Koussa S, et al. Hypertransfusion: a successful method of treatment in thalassemia intermedia patients with spinal cord compression secondary to extramedullary hematopoiesis. Spine. 2003;28:E245–E249.
   PubMedGoogle Scholar
• Castelli R, Graziadei G, Karimi M, et al. Intrathoracic masses due to extramedullary hematopoiesis. Am J Med Sci. 2004;328:299–303.
   Google Scholar
• Smith PR, Manjoney DL, Teitcher JB, et al. Massive hemothorax due to intrathoracic extramedullary hematopoiesis in a patient with thalassemia intermedia. Chest. 1988;94:658–660.
   PubMedGoogle Scholar
• Saxon BR, Rees D, Olivieri NF. Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in beta thalassaemia. Br J Haematol. 1998;101:416–419.
   PubMed Web of Science ®Google Scholar
• Cario H, Wegener M, Debatin KM. Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis. Ann Hematol. 2002;81:478–482.
   PubMed Web of Science ®Google Scholar
• Gupta VL, Choubey BS. RBC survival, zinc deficiency, and efficacy of zinc therapy in sickle cell disease. Birth Defects Orig Artic Ser. 1987;23:477–483.
   Google Scholar
• Dettelbach HR, Aviado DM. Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication. J Clin Pharmacol. 1985;25:8–26.
   PubMed Web of Science ®Google Scholar
• al Momen AK. Recombinant human erythropoietin induced rapid healing of a chronic leg ulcer in a patient with sickle cell disease. Acta Haematol. 1991;86:46–48.
   Google Scholar
• Gimmon Z, Wexler MR, Rachmilewitz EA. Juvenile leg ulceration in beta-thalassemia major and intermedia. Plast Reconstr Surg. 1982;69:320–325.
   Google Scholar
• Taher A, Isma'eel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96:488–491.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Robbiolo L, Bottasso BM, et al. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol. 2000;111:467–473.
   PubMed Web of Science ®Google Scholar
• Pignatti BC, Carnelli V, Caruso V, et al. Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol. 1998;99:76–79.
   PubMedGoogle Scholar
• Manfre L, Giarratano E, Maggio A, et al. MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. AJR Am J Roentgenol. 1999;173:1477–1480.
   PubMed Web of Science ®Google Scholar
• Atichartakarn V, Likittanasombat K, Chuncharunee S, et al. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Int J Hematol. 2003;78:139–145.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127:1523–1530.
   PubMed Web of Science ®Google Scholar
• Gharzuddine WS, Kazma HK, Nuwayhid IA, et al. Doppler characterization of left ventricular diastolic function in beta-thalassaemia major. Evidence for an early stage of impaired relaxation. Eur J Echocardiogr. 2002;3:47–51.
   Google Scholar
• Isma'eel H, Chafic AH, Rassi FE, et al. Relation between iron-overload indices, cardiac echo-Doppler, and biochemical markers in thalassemia intermedia. Am J Cardiol. 2008;102:363–367.
   PubMed Web of Science ®Google Scholar
• Derchi G, Forni GL, Formisano F, et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica. 2005;90:452–458.
   PubMed Web of Science ®Google Scholar
• Savona-Ventura C, Bonello F. Beta-thalassemia syndromes and pregnancy. Obstet Gynecol Surv. 1994;49:129–137.
   PubMedGoogle Scholar
• Skordis N, Christou S, Koliou M, et al. Fertility in female patients with thalassemia. J Pediatr Endocrinol Metab. 1998;11:35–943.
   Google Scholar
• Karagiorga-Lagana M. Fertility in thalassemia: the Greek experience. J Pediatr Endocrinol Metab. 1998;11:945–951.
   PubMed Web of Science ®Google Scholar
• Nassar A, Naja M, Cesaretti C, et al. Pregnancy outcome in patients with beta-thalassemia intermedia at two tertiary care centers, in Beirut and Milan. Haematologica. 2008;93:1586–1587.
   PubMed Web of Science ®Google Scholar
• Cadili A, de Gara C. Complications of splenectomy. Am J Med. 2008;121:371–375.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–1193.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Kati M, Meletis J. Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion. 2007;47:792–800.
   PubMed Web of Science ®Google Scholar
• Eder AF, Chambers LA. Noninfectious complications of blood transfusion. Arch Pathol Lab Med. 2007;13:708–718.
   Google Scholar
• Cossu P, Toccafondi C, Vardeu F, et al. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. Eur J Pediatr. 1981;137:267–271.
   PubMed Web of Science ®Google Scholar
• Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol. 2003;122:305–310.
   PubMed Web of Science ®Google Scholar
• Olivieri NF. Reactivation of fetal hemoglobin in patients with beta-thalassemia. Semin Hematol. 1996;33:24–42.
   PubMed Web of Science ®Google Scholar
• Arruda VR, Lima CS, Saad ST, et al. Successful use of hydroxyurea in beta-thalassemia major. N Engl J Med. 1997;336:964.
   PubMed Web of Science ®Google Scholar
• Bradai M, Abad MT, Pissard S, et al. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood. 2003;102:1529–1530.
   PubMed Web of Science ®Google Scholar
• Dixit A, Chatterjee TC, Mishra P, et al. Hydroxyurea in thalassemia intermedia-a promising therapy. Ann Hematol. 2005;84:441–446.
   PubMed Web of Science ®Google Scholar
• Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27:380–385.
   PubMed Web of Science ®Google Scholar
• Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetalglobin- gene expression in the beta-globin disorders. N Engl J Med. 1993;328:81–86.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Graziadei G, Ciceri L, et al. Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study. Blood Cells Mol Dis. 2000;26:105–111.
   Google Scholar
• Sher GD, Ginder GD, Little J, et al. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. N Engl J Med. 1995;332:1606–1610.
   PubMed Web of Science ®Google Scholar
• Collins AF, Pearson HA, Giardina P, et al. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood. 1995;85:43–49.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Rees DC, Ginder GD, et al. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet. 1997;350:491–492.
   PubMed Web of Science ®Google Scholar
• Piga A, Longo F, Voi V, et al. Late effects of bone marrow transplantation for thalassemia. Ann NY Acad Sci. 1998;850:294–299.
   PubMed Web of Science ®Google Scholar
• Apperley JF. Bone marrow transplant for the haemoglobinopathies: past, present and future. Baillieres Clin Haematol. 1993;6:299–325.
   Google Scholar
• Uckan D, Cetin M, Yigitkanli I, et al. Life-threatening neurological complications after bone marrow transplantation in children. Bone Marrow Transplant. 2005;35:71–76.
   PubMed Web of Science ®Google Scholar
• Khojasteh NH, Zakernia M, Ramzi M, et al. Bone marrow transplantation for hematological disorders-Shiraz experience. Indian J Pediatr. 2002;69:31–32.
   Google Scholar
• Rund D, Rachmilewitz E. Advances in the pathophysiology and treatment of thalassemia. Crit Rev Oncol Hematol. 1995;20:237–254.
   Google Scholar